Document is current

Article History

Received: 7 May 2024

Accepted: 7 November 2024

First Online: 18 November 2024

Declarations

:

: This study, using de-identified human iMSCs, was reviewed by the institutional review board (IRB) (KWNUIRB-2021–04-009–002): (1) Title of the approved project: Development of next-generation therapeutic agents for autoimmune diseases using advanced mesenchymal stem cell-derived materials; (2) Name of the institutional approval committee: IRB of Kangwon National University; (3) Approval number: KWNUIRB-2021–04-009–002; (4) Date of approval: May 17, 2022. The animal studies were reviewed and approved (KW-211020–1) by the IACUC of Kangwon National University and the IACUC of GenNBio (GN-IACUC-22–05-07) as follows: Experiment to obtain splenocytes from a murine model of SLE: (1) Title of the approved project: The effects of advanced mesenchymal stem cell-derived materials on SLE; (2) Name of the institutional approval committee: IACUC of Kangwon National University; (3) Approval number: KW-211020–1; (4) Date of approval: October 26, 2021; In vivo study: (1) Title of the approved project: The therapeutic effect of advanced exosome in a murine model of SLE; (2) Name of the institutional approval committee: IACUC of GenNBio; (3) Approval number: GN-IACUC-22–05-07; (4) Date of approval: May 11, 2022.

: Not applicable.

: EWC is listed as an inventor on a pending patent that describes the “Mesenchymal stem cells primed with disease-condition-immune cells and uses thereof.” Since EWC and her institute stand to profit from this work, EWC has a conflict of interest in this capacity, which has hereby been officially disclosed. JL, BC, and SK are employees of GenNBio Inc. The remaining authors declare no competing interests.